Rain Therapeutics Inc
Change company Symbol lookup
Select an option...
RAIN Rain Therapeutics Inc
HYHG.EU ProShares High Yield-Interest Rate Hedged
DIDIY DiDi Global Inc
AWK American Water Works Company Inc
ASO Academy Sports and Outdoors Inc
GAB Gabelli Equity Trust
STRC Sarcos Technology and Robotics Corp
RLMD Relmada Therapeutics Inc
LMND Lemonade Inc
NAACW North Atlantic Acquisition Equity Warrant Exp 20 Oct 2025 *W EXP 10/20/2025

Health Care : Pharmaceuticals |
Company profile

Rain Therapeutics Inc. (Rain) is a late-stage precision oncology company developing therapies that target oncogenic drivers. The Company’s lead product candidate, Milademetan (RAIN-32) is a small molecule, oral inhibitor of mouse double minute 2 (MDM2), which may be oncogenic in numerous cancers. RAIN-32 is being evaluated in an ongoing Phase III clinical trial in patients with LPS, as well as a Phase II tumor-agnostic basket trial in certain solid tumors (MANTRA-2). Rain is commencing a Phase II clinical trial of milademetan (MANTRA-3), for the treatment of patients with Merkel cell carcinoma. In addition to RAIN-32, the Company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. The MANTRA-3 trial is designed to evaluate the efficacy of milademetan, as a monotherapy in patients with MCC. Rain is also developing a preclinical program focused on targeting RAD52 in the deoxyribonucleic acid damage repair pathway.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:
  • Prev Close
  • Today's Open
  • Day's Range
  • Avg Vol (10-day)
  • Last (time)
    4:00p ET 09/27/22
  • Last (size)
  • 52-Wk Range
    2.15 - 17.31
  • (11/10/21 - 05/26/22)
  • 106.6%
  • Market Cap
  • Shares Outstanding
  • -2.69
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • --
  • 78.78
  • (% of float 09/15/22)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.